14:01 · 20 December 2024

BREAKING: Novo Nordisk shares lose 20% amid weak performance by CagriSema🚨

Novo Nordisk
Shares
NOVOB.DK, Novo Nordisk A/S
-
-

Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

 

The company's shares are trading at their lowest since August 2023. Source: xStation 

13 October 2025, 22:20

Bank earnings could fill US economic data vacuum

13 October 2025, 17:05

Goldman Sachs boosts sentiment on Estée Lauder shares 💡

13 October 2025, 15:28

US OPEN: "Green" Start to the Week on Wall Street

13 October 2025, 14:37

OpenAI Announces Partnership with Broadcom. Company Shares Soar!

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Join over 1.7 Million investors from around the world